Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease
NCT05768334
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
116
Enrollment
OTHER
Sponsor class
Conditions
NAFLD
Interventions
DRUG:
Lubiprostone 24Mcg Oral twice daily
Sponsor
Helwan University